iX Biopharma Ltd.

(Company Registration No. 200405621W)

UNAUDITED CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX MONTHS AND
FULL YEAR ENDED 30 JUNE 2021

Unaudited Condensed Interim Consolidated Statement of Comprehensive Income

for six months and full year ended 30 June 2021

	Note	Group 6 months ended			Group 12 months ended		
		30.06.21 S$'000	30.06.20 S$'000	%	30.06.21 S$'000	30.06.20 S$'000	%
Revenue	5.3	915	691	32	1,745	985	77
Cost of sales		(1,140)	(883)	29	(2,127)	(1,572)	35
Gross Loss		**(225)**	**(192)**	17	**(382)**	**(587)**	(35)
Other income		651	608	7	1,575	1,046	51
Expenses							
- Research and development		(1,456)	(1,262)	15	(2,747)	(2,499)	10
- Sales and marketing		(1,154)	(1,068)	8	(2,249)	(2,259)	-
- General and administrative		(2,786)	(3,253)	(14)	(6,051)	(6,346)	(5)
- Others		(359)	552	nm	1,795	384	367
- Finance expense		(92)	(119)	(23)	(174)	(238)	(27)
Total expenses		(5,847)	(5,150)	14	(9,426)	(10,958)	(14)
Loss before income tax		(5,421)	(4,734)	15	(8,233)	(10,499)	(22)
Income tax expense		-	-		(1)	-	nm
Loss for the financial period		**(5,421)**	**(4,734)**	15	**(8,234)**	**(10,499)**	**(22)**
Other comprehensive income:							
Items that may be reclassified subsequently to profit or loss:							
Currency translation differences arising from consolidation							
- (Loss)/gain		274	(469)	nm	(1,400)	(370)	278
Total comprehensive loss		**(5,147)**	**(5,203)**	(1)	**(9,634)**	**(10,869)**	**(11)**
Loss per share attributable to equity holders of the Company (cent per share)							
Basic loss per share	7	(0.78)	(0.73)		(1.20)	(1.62)	
Diluted loss per share	7	(0.78)	(0.73)		(1.20)	(1.62)	

nm: not meaningful

The Unaudited Consolidated Interim Statement of Comprehensive Income should be read in conjunction with the 2020 Audited Financial Statements and the accompanying explanatory notes attached to this financial report.

Unaudited Condensed Interim Balance Sheets
As at 30 June 2021

	Note	Group		Company	
		30.06.21	30.06.20	30.06.21	30.06.20
		S$'000	S$'000	S$'000	S$'000
ASSETS					
Current assets					
Cash and cash equivalents	8	6,205	5,663	5,173	3,593
Trade and other receivables		1,816	1,300	19,105	15,816
Inventories		1,103	883	21	-
Other current assets		227	297	183	206
		9,351	8,143	24,482	19,615
Non-current assets					
Deposits		148	105	83	-
Intangible assets	9	413	447	72	108
Property, plant and equipment	10	8,338	8,026	166	189
Right of use assets	11	607	261	594	230
Investments in subsidiaries		-	-	1,966	1,966
		9,506	8,839	2,881	2,493
Total assets		18,857	16,982	27,363	22,108
LIABILITIES					
Current liabilities					
Trade and other payables		2,808	2,824	1,740	1,709
Borrowings	12	421	216	25	25
Lease liabilities	12	375	245	361	226
Provision		63	12	-	-
		3,667	3,297	2,126	1,960
Non-current liabilities					
Borrowings	12	3,201	3,438	30	55
Lease liabilities	12	238	19	238	6
Provision		40	60	-	-
		3,479	3,517	268	61
Total liabilities		7,146	6,814	2,394	2,021
NET ASSETS		11,711	10,168	24,969	20,087
EQUITY					
Capital and reserves attributable to equity holders of the Company					
Share capital	13	83,337	72,251	83,337	72,251
Other reserves		344	1,653	411	320
Accumulated losses		(71,970)	(63,736)	(58,779)	(52,484)
Total equity		11,711	10,168	24,969	20,087

The Unaudited Consolidated Interim Balance Sheets should be read in conjunction with the 2020 Audited Financial Statements and the accompanying explanatory notes attached to this financial report.

Unaudited Condensed Interim Statements of Changes in Equity
for six months and full year ended 30 June 2021

	Attributable to equity holders of the Company				
Group	**Share capital**	**Share based payment reserve**	**Currency translation reserve**	**Accumulated losses**	**Total equity**
	S$'000	S$'000	S$'000	S$'000	S$'000
Balance as at 30 June 2020	**72,251**	**320**	**1,333**	**(63,736)**	**10,168**
Loss for the period	-	-	-	(8,234)	(8,234)
Other comprehensive loss for the period	-	-	(1,400)		(1,400)
Total comprehensive loss for the period	-	-	(1,400)	(8,234)	(9,634)
Share based payment scheme					
- Value of employees' services	-	997	-	-	997
- Shares issued pursuant to iX Performance Share Plan	906	(906)	-	-	-
Shares issued pursuant to private placement, net of transaction cost	10,180	-	-	-	10,180
Total transactions with owners, recognised directly in equity	11,086	91	-	-	11,177
Balance as at 30 June 2021	**83,337**	**411**	**(67)**	**(71,970)**	**11,711**
Balance as at 30 June 2019	**71,525**	**508**	**1,703**	**(53,237)**	**20,499**
Loss for the period	-	-	-	(10,499)	(10,499)
Other comprehensive gain for the period	-	-	(370)	-	(370)
Total comprehensive gain/(loss) for the period	-	-	(370)	(10,499)	(10,869)
Share based payment scheme					
- Value of employees' services	-	538	-	-	538
- Shares issued pursuant to iX Performance Share Plan	726	(726)	-	-	-
Total transactions with owners, recognised directly in equity	726	(188)	-	-	538
Balance as at 30 June 2020	**72,251**	**320**	**1,333**	**(63,736)**	**10,168**

	Attributable to equity holders of the Company			
Company	**Share capital**	**Share based payment reserve**	**Accumulated losses**	**Total equity**
	S$'000	S$'000	S$'000	S$'000
Balance as at 30 June 2020	**72,251**	**320**	**(52,484)**	**20,087**
Loss for the period	-	-	(6,295)	(6,295)
Total comprehensive loss for the period	-	-	(6,295)	(6,295)
Share based payment scheme				
- Value of employees' services	-	997	-	997
- Shares issued pursuant to iX Performance Share Plan	906	(906)	-	-
Shares issued pursuant to private placement, net of transaction cost	10,180	-	-	10,180
Total transactions with owners, recognised directly in equity	11,086	91	-	11,177
Balance as at 30 June 2021	**83,337**	**411**	**(58,779)**	**24,969**
Balance as at 30 June 2019	**71,525**	**508**	**(45,530)**	**26,503**
Loss for the period	-	-	(6,954)	(6,954)
Total comprehensive loss for the period	-	-	(6,954)	(6,954)
Share based payment scheme				
- Value of employees' services	-	538	-	538
- Shares issued pursuant to iX Performance Share Plan	726	(726)	-	-
Total transactions with owners, recognised directly in equity	726	(188)	-	538
Balance as at 30 June 2020	**72,251**	**320**	**(52,484)**	**20,087**

The Unaudited Condensed Interim Statement of Changes in Equity should be read in conjunction with the 2020 Audited Financial Statements and the accompanying explanatory notes attached to this financial report.

Unaudited Condensed Interim Consolidated Statement of Cash Flows

for full year ended 30 June 2021

	Note	Group 12 months ended 30.06.21 S$'000	30.06.20 S$'000
Cash flows from operating activities			
Total loss after tax		(8,234)	(10,499)
Adjustments for:			
- Depreciation and amortisation expense		1,054	1,049
- Income tax expense		1	-
- Interest income		(7)	(87)
- Interest expense		174	238
- Inventory write-down		175	56
- Provision		27	26
- Disposal of property, plant and equipment		(4)	1
- Research and development tax incentive		(1,230)	(405)
- Share based payment expense		997	538
- Unrealised currency exchange gains – net		(1,708)	(324)
		(8,755)	(9,407)
Changes in working capital:			
- Trade and other receivables		18	(230)
- Other current assets		73	67
- Trade and other payables		(71)	504
- Inventories		(348)	(83)
Cash used in operations		(9,083)	(9,149)
Interest received		7	87
Research and development tax incentive received		725	742
Income tax paid		(1)	-
Net cash used in operating activities		(8,352)	(8,320)
Cash flows from investing activities			
Additions to property, plant and equipment		(553)	(984)
Additions to intangible assets		-	(10)
Disposal of property, plant and equipment		46	-
Net cash used in investing activities		(507)	(994)
Cash flows from financing activities			
Decrease in fixed deposits pledged		622	-
Proceeds from issuance of ordinary shares		10,180	-
Repayment of borrowings		(226)	(213)
Principal payment of lease liabilities		(378)	(375)
Interest paid		(174)	(238)
Net cash from/(used in) financing activities		10,024	(826)
Net increase/(decrease) in cash and cash equivalents		1,165	(10,140)
Cash and cash equivalents			
Beginning of financial period		4,470	14,709
Effects of currency translation on cash and cash equivalents		(50)	(99)
End of financial period	8	5,585	4,470

The Unaudited Condensed Interim Consolidated Statement of Cash Flows should be read in conjunction with the 2020 Audited Financial Statements and the accompanying explanatory notes attached to this financial report.

A NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE SIX MONTHS AND FULL YEAR ENDED 30 JUNE 2021

1. GENERAL INFORMATION

iX Biopharma Ltd. (the "Company") is a public limited liability company, incorporated and domiciled in Singapore. The address of its registered office is 80 Robinson Road, #02-00 Singapore 068898. The address of its principal place of business is 1 Kim Seng Promenade, #14-01 Great World City East Tower, Singapore 237994.

The principal activities of the Group are the development, manufacture and commercialisation of innovative therapies for the treatment of acute and breakthrough pain, and other health conditions.

The Company is listed on the Catalist Board of the Singapore Exchange Securities Trading Limited (SGX-ST).

2. BASIS OF PREPARATION

a) Basis of accounting

These consolidated financial statements are unaudited and prepared in accordance with SFRS(I) 1-34 Interim Financial Reporting issued by the Accounting Standards Council Singapore. They do not include all of the information required for full annual financial statements and should be read in conjunction with the last audited annual financial statements for the year ended 30 June 2020 (2020 Audited Financial Statements).

The 2020 Audited Financial Statements were prepared under Singapore Financial Reporting Standards (International) (SFRS(I)).

b) Significant accounting policies

The accounting policies and presentation adopted for this unaudited consolidated interim financial report are consistent with those adopted for the 2020 Audited Financial Statements.

c) New and amended standards adopted by the Group

The Group has adopted all the applicable new and revised Singapore Financial Reporting Standards (International) (SFRS(I)) and Interpretations of SFRS(I) (INT SFRS(I)) that are mandatory for the accounting periods beginning on or after 1 July 2020. The adoption of these new and revised SFRS(I) and INT SFRS(I) did not result in any substantial change to the Group's and the Company's accounting policies and has no significant impact on the financial statements for the current financial reporting period.

3. USE OF JUDGEMENTS AND ESTIMATES

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 30 June 2020.

4. SEASONALITY OF OPERATIONS

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial period.

5. SEGMENT AND REVENUE INFORMATION

5.1 Reportable segments

The Group's business comprises of the Specialty Pharmaceutical and Nutraceutical segments.

Specialty Pharmaceutical's primary business activities are the development and manufacturing of products, and sales of pharmaceutical and medicinal cannabis products.

Nutraceutical's primary business activities are the sale of nutraceutical products.

	Group			Group		
	6 months ended 30.06.21			12 months ended 30.06.21		
	Specialty Pharmaceuticals	Nutraceuticals	Total	Specialty Pharmaceuticals	Nutraceuticals	Total
	S$000	S$000	S$000	S$000	S$000	S$000
Total segment sales	573	451	1,024	1,119	939	2,058
Less:						
Inter-segment sales	(109)	-	(109)	(313)	-	(313)
Sales to external parties	464	451	915	806	939	1,745
Adjusted EBITDA	(2,254)	(747)	(3,001)	(4,045)	(1,433)	(5,478)
Depreciation	292	-	292	594	-	594
Amortisation	9	-	9	17	-	17

	6 months ended 30.06.20			12 months ended 30.06.20		
	Specialty Pharmaceuticals	Nutraceuticals	Total	Specialty Pharmaceutical	Nutraceuticals	Total
	S$000	S$000	S$000	S$000	S$000	S$000
Total segment sales	577	259	836	787	389	1,176
Less:						
Inter-segment sales	(145)	-	(145)	(191)	-	(191)
Sales to external parties	432	259	691	596	389	985
Adjusted EBITDA	(2,067)	(1,258)	(3,325)	(4,247)	(1,895)	(6,142)
Depreciation	277	-	277	593	-	593
Amortisation	16	-	16	25	-	25

	Group		Group	
	6 months ended		12 months ended	
	30.06.21	30.06.20	30.06.21	30.06.20
	S$000	S$000	S$000	S$000
Adjusted EBITDA is reconciled to loss before income tax as follows:				
Reportable segments	(3,001)	(3,325)	(5,478)	(6,142)
Unallocated corporate expenses	(1,646)	(1,270)	(3,562)	(3,408)
	(4,647)	(4,595)	(9,040)	(9,550)
Research and development tax incentive	611	188	1,230	405
Depreciation	(496)	(512)	(1,001)	(1,024)
Amortisation	(27)	(16)	(53)	(25)
Currency exchange gains/(losses) - net	(359)	552	1,795	384
Share based payment expense	(413)	(254)	(997)	(538)
Finance expense	(92)	(119)	(174)	(238)
Interest income	2	22	7	87
Loss before income tax	(5,421)	(4,734)	(8,233)	(10,499)

5.2 Geographical segments

The Group's two business segments operate in three geographical areas.

	Group		Group	
	6 months ended		12 months ended	
	30.06.21 S$000	30.06.20 S$000	30.06.21 S$000	30.06.20 S$000
Net sales				
China	472	308	870	308
Australia	393	360	786	627
Singapore	50	23	89	50
	915	691	1,745	985

	30.06.21	30.06.20
	S$000	S$000
Non-current assets		
Singapore	915	526
Hong Kong	65	105
Australia	8,526	8,208
	9,506	8,839

5.3 Revenue from contracts with customers

During the financial year, the Group derives revenue from the transfer of goods and services at a point in time and over time in the following categories:

	Group			Group		
	6 months ended 30.06.21			12 months ended 30.06.21		
	At a point in time	Over time	Total	At a point in time	Over time	Total
	S$000	S$000	S$000	S$000	S$000	S$000
Sale of goods:						
- Specialty Pharmaceuticals	130	-	130	274	-	274
- Nutraceuticals	451	-	451	939	-	939
	581	-	581	1,213	-	1,213
Services rendered:						
- Development and manufacturing services	-	334	334	-	532	532
Total	581	334	915	1,213	532	1,745

	Group			Group		
	6 months ended 30.06.20			12 months ended 30.06.20		
	At a point in time	Over time	Total	At a point in time	Over time	Total
	S$000	S$000	S$000	S$000	S$000	S$000
Sale of goods:						
- Specialty Pharmaceuticals	171	-	171	224	-	224
- Nutraceuticals	259	-	259	392	-	392
	430	-	430	616	-	616
Services rendered:						
- Development and manufacturing services	150	111	261	150	219	369
Total	580	111	691	766	219	985

5.4 Breakdown of the Group's net sales & operating Loss after tax

	Group	Group	
	12 months ended 30.06.21	12 months ended 30.06.20	%
	S$'000	S$'000	
Net sales			
- First half year	830	294	182
- Second half year	915	691	32
Operating loss after tax			
- First half year	(2,813)	(5,765)	(51)
- Second half year	(5,421)	(4,734)	15

6. LOSS BEFORE TAX

Loss before tax includes the following items that are either unusual because of their nature, size or incidence; or required by disclosure provisions of Catalist Rules of SGX-ST:

	Group		Group	
	6 months ended		12 months ended	
	30.06.21	30.06.20	30.06.21	30.06.20
	S$'000	S$'000	S$'000	S$'000
Gains:				
Research and development tax incentive	611	188	1,230	405
Interest income	2	22	7	87
Government grants	37	20	120	20
Rental income	-	135	169	273
Currency exchange gains - net	-	552	1,795	384
Expenses:				
Share-based payment expense	413	254	997	538
Depreciation and amortisation expense				
- Property, plant and equipment	304	315	620	646
- Right of use assets	192	197	381	378
- Intangible assets	27	16	53	25
Inventory write-down	175	56	175	56
Currency exchange losses - net	359	-	-	-
Interest expense	92	119	174	238

7. EARNINGS PER ORDINARY SHARE

	Group		Group	
	6 months ended		12 months ended	
	30.06.21	30.06.20	30.06.21	30.06.20
Net loss attributable to equity holders of the Company (S$'000)	(5,421)	(4,734)	(8,234)	(10,499)
Weighted average number of shares outstanding ('000)	696,928	648,894	687,409	647,285
Basic loss per share (Cents per share)	(0.78)	(0.73)	(1.20)	(1.62)
Diluted loss per share (Cents per share)	(0.78)	(0.73)	(1.20)	(1.62)

The Company has 2,350,000 share awards under iX Performance Share Plan (30 June 2020: 2,384,000 shares awards) which could potentially dilute basic earnings per share in the future but were not included in the calculation of diluted loss per share above because they are antidilutive and having the effect of decreasing the loss per share.

8. CASH AND CASH EQUIVALENTS

For the purpose of presenting the consolidated statement of cash flows, cash and cash equivalent comprise the following:

	Group	
	30.06.21	30.06.20
	S$'000	S$'000
Cash and cash equivalents in Balance Sheet	6,205	5,663
Less: Bank deposits pledged	(620)	(1,193)
Cash and cash equivalents per consolidated statement of cash flows	5,585	4,470

Bank deposits are pledged as security for credit facilities.

9. INTANGIBLE ASSETS

	Group	
	30.06.21	30.06.20
	S$'000	S$'000
Composition		
Goodwill arising on consolidation	327	310
Computer software	179	174
	506	484
Less: accumulated amortisation	(93)	(37)
Intangible assets, net	413	447

During the year ended 30 June 2021, the Group did not acquire any computer software (30 June 2020: S$12,000).

Amortization expense for the six and 12 months ended 30 June 2021 was S$27,000 and S$53,000, respectively (2020: S$16,000; S$25,000).

10. PROPERTY, PLANT AND EQUIPMENT

	Group	
	30.06.21	30.06.20
	S$'000	S$'000
Freehold land	2,882	2,734
Leasehold improvement	250	239
Building	1,965	1,851
Plant and equipment	6,424	5,691
Computer & Office Equipment	280	247
Motor vehicles	238	236
Furniture and fittings	122	124
	12,161	11,122
Less: accumulated depreciation	(3,823)	(3,096)
Property, plant and equipment, net	8,338	8,026

During the year ended 30 June 2021, the Group acquired assets amounting to S$553,000 (30 June 2020: S$1,009,000) and disposed of assets amounting to S$40,000 in net asset value (30 June 2020: S$24,000)

Depreciation expense for the six and twelve months ended 30 June 2021 was S$304,000 and S$620,000, respectively (2020: S$315,000; S$646,000).

Impairment tests

As the Group is still undergoing clinical trials for its pharmaceutical products and has not commenced large scale manufacturing and sale of these products, it has incurred operating losses since its commencement of research and development activities. As such, management has conducted an impairment testing for goodwill, intangible assets, property, plant and equipment (PPE) and right-of-use assets.

Specialty Pharmaceuticals segment and Nutraceuticals segment are identified to be the cash-generating units (CGU) of the Group.

No impairment review was performed for the Nutraceuticals CGU; this is on the basis that there is no goodwill, intangible assets or significant PPE allocated to the CGU, since the nature of its business is the distribution of nutraceutical products that are contract manufactured by the Specialty Pharmaceuticals CGU.

Freehold land and building

For freehold land and building, management compared its net book value against the fair value determined by an external professional valuer to ascertain whether there had been any impairment indicator.

The impairment review carried out as at 30 June 2021 has revealed that the recoverable amount of freehold land and building is higher than the carrying amount. There is no indication of impairment.

Goodwill, intangible assets and other PPE and right-of-use assets

Critical assumptions used for the value-in-use calculations for Specialty Pharmaceuticals CGU:

- Discount rate of 14% (2020: 14%)
- Terminal growth rate of 2% for goodwill (2020: 2%) and no terminal growth rate applied to depreciable intangible assets and PPE
- Annual revenue growth rates of above 100% for FY 2022 to FY 2025, between 26% to 51% for FY 2026 to FY 2027, and between 4% to 15% for FY 2028 to FY 2031 (2020: Annual revenue growth rates of above 100% for FY2021 to FY2023, between 31% to 92% for FY2024 to FY2025, and between 3% to 11% for FY2026 to FY2030)

Management determined the terminal growth rate based on the long-term average growth rates in the industry and its expectations of future market developments. The discount rate used was a pre-tax rate and reflected specific risks relevant to the segment. The annual revenue growth rate was determined based on management's forecast of the projected number of patients who will use the products and the respective products selling price.

The impairment review carried out as at 30 June 2021 revealed that the recoverable amount of the Specialty Pharmaceuticals CGU is higher than the carrying amount. No impairment loss is recognised during the financial year. As at 30 June 2021, any reasonably possible change to the key assumptions applied is not likely to cause the recoverable amount to be below the carrying amount of the Specialty Pharmaceuticals CGU.

For Specialty Pharmaceuticals CGU, the recoverable amount was determined based on fair value less costs of disposal for freehold land and building and based on value-in-use for goodwill, intangible assets, other PPE and right-of-use assets. The cash flow forecast was based on expected revenue growth over a 10-year period. Management determined that a 10-year forecast is appropriate as key products of this business segment, which are still undergoing clinical trials and further development, will require more than 5 years to reach a steady state of sales.

11. RIGHT OF USE ASSETS

The Group leases office space, staff accommodation, and office equipment for business operations from non-related parties.

During the year, the Company exercised its options to extend the leases of its office and staff accommodation for another two years and recognised additional the right of use assets and lease liabilities of S$726,000 respectively for the Group and the Company.

12. BORROWINGS AND LEASE LIABILITIES

Unsecured loans are lease liabilities recognised under SFRS(I) 16. Secured loans are bank borrowings and secured over land and building, certain plant and equipment, motor vehicles and certain bank deposits of subsidiaries of the Group.

	30.06.21			30.06.20		
	Unsecured	Secured	Total	Unsecured	Secured	Total
	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000
Amount repayable in one year or less	375	421	796	245	216	461
Amount repayable after one year	238	3,201	3,439	19	3,438	3,457
Total	**613**	**3,622**	**4,235**	**264**	**3,654**	**3,918**

Reconciliation of liabilities arising from financing activities:

			Non-cash changes				
	Beginning of Financial Year	Principal and interest payments	Adoption of SFRS(I) 16	Addition during the year	Interest expense	Foreign exchange movement	End of Financial Year
	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000
2021							
Bank borrowings	3,654	(375)	-	-	149	194	3,622
Lease liabilities	264	(402)	-	726	25	-	613
2020							
Bank borrowings	3,831	(426)	-	-	213	36	3,654
Lease liabilities	-	(400)	639	-	25	-	264

13. SHARE CAPITAL

Group & Company	6 months ended 30.06.21		12 months ended 30.06.21	
	No. of ordinary shares	Amount	No. of ordinary shares	Amount
		S$'000		S$'000
At beginning of period	696,853,023	83,220	648,894,390	72,251
Shares issued pursuant to				
- Private placement	-	-	44,491,299	10,180
- iX Performance Share Plan	500,000	117	3,967,334	906
At end of period	**697,353,023**	**83,337**	**697,353,023**	**83,337**

Group & Company	6 months ended 30.06.20		12 months ended 30.06.20	
	No. of ordinary shares	Amount	No. of ordinary shares	Amount
		S$'000		S$'000
At beginning of period	648,894,390	72,251	644,594,057	71,525
Shares issued pursuant to				
- iX Performance Share Plan	-	-	4,300,333	726
At end of period	**648,894,390**	**72,251**	**648,894,390**	**72,251**

During the 12 months ended 30 June 2021,

- On 10 September 2020, the Company completed a private placement of 44,491,299 ordinary shares for a net consideration of $10.18 million;
- On 23 October 2020, the Company announced total awards of 3,433,334 shares to certain employees and executives under iX Performance Share Plan (iX PSP);
- On 30 October and 20 November 2020, the Company issued 3,467,334 ordinary shares in aggregate pursuant to iX PSP; and

- On 3 June 2021, the Company announced an award of 500,000 shares an executive under iX PSP and issued these shares pursuant to iX PSP on 4 June 2021.

No share or award was granted to a director or controlling shareholder (and each of their associates). The Company has not granted any options under iX Employee Share Option Scheme since its inception up to 30 June 2021.

Save as disclosed, there are no other changes in the Company's share capital arising from any rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous reported period.

	Number of outstanding share awards / share options	Number of Shares that may be issued upon exercise of options / release of awards
As at 30 June 2021		
iX Performance Share Plan	2,350,000	2,350,000
As at 30 June 2020		
iX Performance Share Plan	2,384,000	2,384,000

The Company did not hold any treasury shares as at 30 June 2021 and 30 June 2020.

The Company's subsidiaries do not hold any shares in the Company as at 30 June 2021 and 30 June 2020.

14. NET ASSET VALUE PER ORDINARY SHARE

	Group		Company	
	30.06.21	30.06.20	30.06.21	30.06.20
Net asset value per ordinary share (in cents)	1.7	1.6	3.6	3.1

The net asset value per ordinary share of the Group and the Company as at 30 June 2021 were calculated based on the total number of issued shares of 697,353,023 (30 June 2020: 648,894,390).

There were no treasury shares as at 30 June 2021 and 30 June 2020.

15. RELATED PARTY TRANSACTIONS

Other than remuneration paid to key management personnel, the Group has no other significant related party transactions.

	Group		Group	
	6 months ended		12 months ended	
	30.06.21	30.06.20	30.06.21	30.06.20
	S$'000	S$'000	S$'000	S$'000
Key management personnel compensation:				
Wages, salaries and other short-term employee benefits	1,105	1,011	2,142	1,902
Employer's contribution to defined contribution plan	15	4	26	9
Share based payment expense	256	107	622	189
	1,376	1,122	2,790	2,100

16. CAPITAL COMMITMENTS

Capital expenditure of $57,000 (2020: $196,000) for property, plant and equipment were contracted for at the balance sheet date but not recognised in the financial statements.

17. CHANGES IN THE COMPOSITION OF THE GROUP

On 2 November 2020, the Company incorporated iX Biopharma Europe Limited, a wholly owned subsidiary in Republic of Ireland with an initial share capital of €1.00, whose principal activities are product marketing and distribution in Europe.

On 31 March 2021, the Company incorporated Ligo Pharma Limited, a wholly owned subsidiary in Cayman Islands with an initial share capital of US$1.00, whose principal activities are those of investment holding.

The incorporations were funded through internal resources and is not expected to have any material impact on the consolidated net tangible assets.

18. SUBSEQUENT EVENT

The Company completed the rights issue of 48,814,711 ordinary shares for a total net proceeds of $9.61 million on 26 July 2021.

The total number of shares after rights issue is 746,167,734.

B ADDITIONAL INFORMATION REQUIRED BY CATALIST RULES FOR SIX MONTHS AND YEAR ENDED 30 JUNE 2021

1. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following:

(a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and

(b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.

Overview

WaferiX is a sublingual dosage form that improves bioavailability of active ingredients, providing patients and users with rapid absorption, faster therapeutic action and predictable outcome. The Group leverages WaferiX in the development of its pharmaceutical and nutraceutical products. The Group's strategy is to use WaferiX to repurpose drugs. Drug repurposing is where already approved active pharmaceutical ingredients are developed into drugs with a sublingual new dosage form and/or to address new indications.

WaferiX has the ability to create market differentiation in response to expiring patents, generic encroachment, and declining new drug pipeline. We have identified certain conditions and actives that have the potential to benefit from WaferiX. In addition to pain and erectile dysfunction, we have broadened our product pipeline to include new therapeutic areas including psychiatry, oncology and vaccines.

During the six months ended 30 June 2021 (2H21), the Group successfully installed its additional freeze-dry wafer production equipment which had been delayed for a year due to the onset of the pandemic. With the new freeze-dry equipment in place, the Group's production capacity for its WaferiX sublingual wafers will be boosted by up to six times the current capacity. The first commercial batch of wafers from the new equipment was manufactured in July 2021 and the Group expects to benefit from improved operational efficiency and economies of scale. The expanded wafer production capacity will allow the Group to pursue new commercial partnerships for its medicinal cannabis and Entity nutraceutical wafer products, invest in marketing opportunities and expand into new markets.

The Group focused on securing commercial partnerships and e-commerce nutraceutical sales during the period, as in-person sales activities remained challenging compared to pre-pandemic conditions due to continued social distancing measures, intermittent lockdown and border closures imposed to curb the rates of infection in Australia and Singapore.

Pharmaceuticals

Wafermine

Wafermine is the world's first sublingual ketamine to be developed for moderate to severe acute pain. In addition to the treatment of pain, Wafermine is Phase 2-ready for major depressive disorder (MDD). In recent decades, racemic ketamine has also proven to be effective for treatment-resistant depression (TRD).

In May 2021, the US FDA granted the Company an orphan drug designation for the treatment of patients with Complex Regional Pain Syndrome (CRPS) with ketamine. The orphan drug status provides certain benefits, including market exclusivity of seven years upon regulatory approval, tax credits for qualified clinical trials and waiver of the FDA's New Drug Application filing fee of approximately US$2.9 million. The inclusion of CRPS adds to an already valuable Wafermine asset, which is currently being developed for acute moderate to severe pain and, potentially, major depressive disorder. CRPS opens up a new market with significant unmet medical need. This increases the attractiveness of Wafermine to licensees, who will be able to unlock substantially more value across multiple conditions.

During the period, we engaged with pharmaceutical companies based in US and EU who indicated interest following their commercial evaluation of Wafermine in the markets that they operate in.

Wafermine is currently supplied to hospitals in Australia under Schedule 5A of the Therapeutic Goods Regulations (TGR) as an unregistered medicine.

Medicinal Cannabis

Xativa contains CBD delivered using the Group's patented WaferiX sublingual delivery technology. Xativa is currently prescribed for a wide variety of conditions including treating anxiety, relieving pain, reducing

inflammation, and improving sleep quality, among other conditions, to patients who are not effectively treated with other drugs.

The Xativa range is available as an unregistered medicine by doctors' prescription under the Special Access Scheme and Authorised Prescriber pathway in Australia. It is distributed through both wholesale distribution channels and directly to retail pharmacies.

During the period, the Group obtained export listing status for Xativa from the TGA. This demonstrates the product's compliance with strict standards that apply similarly to products supplied in Australia. The Group has signed supply agreements with partners in Brazil and New Zealand to distribute and market our medicinal cannabis range to doctors and patients in those markets, subject to regulatory requirements being fulfilled.

Other Pharmaceuticals

In Australia, we supply Wafesil and Silcap, our sildenafil products for the treatment of male erectile dysfunction, through telemedicine and pharmacy channels. In Singapore, Silcap is supplied through medical clinics.

BnoX is a novel, sublingual buprenorphine wafer developed for the management of acute and chronic moderate to severe pain. BnoX is currently being supplied to hospitals in Australia under Schedule 5A of the TGR as an unregistered medicine.

Product development & manufacturing services

WaferiX has the ability to create market differentiation in response to expiring patents, generic encroachment, and declining new drug pipeline. During the year, we had undertaken product development works using WaferiX on behalf other pharmaceutical companies.

Nutraceuticals

Entity Health

Entity nutraceuticals are sold into China through its two flagship stores launched in April 2020 on Tmall Global and JD Worldwide, cross-border e-commerce platforms. Entity products are also sold into more than 250 pharmacies and health food shops across major cities in Australia.

LumeniX, an innovative sublingual beauty supplement, and the NAD products RestoriX and MetaboliX Plus, nicotinamide supplements designed to boost NAD+ (nicotinamide adenine dinucleotide) levels in the body, continue to be the top-selling products on our stores to the Chinese customers.

Entity has engaged an experienced third-party agency to operate its stores and market its products to the Chinese consumers. We focus our marketing on LumeniX, RestoriX and MetaboliX Plus. To-date we have invested in in-site marketing using tools such as short messaging, search engine optimisation and banner advertisements, and by partnering with influencers to market on other popular platforms such as Little Redbook, Wechat and Weibo.

Review of performance for six months and year ended 30 June 2021 (2H21; FY2021)

Revenue	**2H21**	**2H20**	**Incr/ (Decr)**	**FY2021**	**FY2020**	**Incr/ (Decr)**
	S$'000	**S$'000**		**S$'000**	**S$'000**	**%**
Specialty Pharmaceuticals	464	432	7%	806	596	35%
Nutraceuticals	451	259	74%	939	389	141%
Total revenue	**915**	**691**	**32%**	**1,745**	**985**	**77%**

Total revenue increased by S$0.22 million and S$0.76 million or 32% and 77% during 2H21 and FY2021 over the comparative six months and year ended 30 June 2020 (2H20; FY2020).

Specialty Pharmaceuticals segment achieved an overall growth of 35% in FY2021, mainly from higher product development and manufacturing services. Entity Health, our nutraceutical segment continued to grow its sales particularly from its flagship stores on Tmall Global and JD Worldwide. LumeniX, RestoriX and MetaboliX Plus had posted strong sales on both ecommerce platforms during the Single's Day and 618 sales events in November 2020 and June 2021. Sales grew 74% and 141% over 2H20 and FY2020 respectively.

The Group's cost of sales was S$1.14 million and S$2.13 million in 2H21 and FY2021, as compared to S$0.88 million and S$1.57 million in 2H20 and FY2020, and was largely in line with the increase in revenue. The cost of sales also includes the cost of manufacturing which consists of personnel, material and other fixed overheads.

In FY2021, higher revenue during the 2H21 and FY2021 lowered the Group's gross loss margin to 24.6% and 21.9% respectively as compared to 27.8% and 59.6% in 2H20 and FY2020.

Other income - Research and Development (R&D) Incentive

The Group conducts its R&D activities through its wholly owned subsidiaries in Australia and has been eligible for R&D tax incentive under a programme administered jointly by the Australian Taxation Office (ATO) and Innovation Australia. This incentive provides for a rebate of 43.5% on eligible R&D expenditure incurred in Australia by these subsidiaries. A higher rebate in FY2021 was due to recognition of additional rebates relating to FY2019 and FY2020 R&D activities that were finalised with ATO during the year.

Expenses

The expense items in loss before tax were analysed below:

R&D expense

During the periods, R&D activities were focused on new product development for our medicinal cannabis range and pipelines of pharmaceuticals and nutraceuticals.

Sales and marketing

Since launching Entity on Tmall Global and JD Worldwide, we have rationalised our headcount and advertising activities in Australia and focused our marketing activities on both ecommerce platforms in China. As a result, overall sales and marketing expenses in 2H21 and FY2021 were comparable to those in prior periods despite the material increase in sales.

General and administrative (G&A)

Our regulatory and compliance expenses in FY2021 were lower due to one-off expenses totalling S$0.53 million incurred in FY2020. We also have much lower travelling expenses during this year due to COVID-19 and benefited from cost rationalisation initiated in FY2020.

Despite higher employee share-based compensation awards, overall G&A expenses in 2H21 and FY2021 were lowered by 14% and 5% as compared to 2H20 and FY2020 respectively.

Others

During FY2021, we observed volatility in currency exchange rates, particularly in the Australian dollar. The appreciation of the Australian dollar against the Singapore dollar during the first three quarters significantly favoured our cash holding and receivables from our subsidiaries, denominated in Australian dollars, before depreciating in the last quarter. As a result, we recorded a net loss in currency exchange of S$0.36 million in 2H21 but an overall net gain of S$1.80 million for FY2021.

Review of operating segment results

See above for analysis of revenue by operating segments.

The adjusted EBITDA loss of specialty pharmaceutical segment was S$4.05 million as compared to S$4.25 million in FY2020. The lower loss was principally due to the higher revenue earned during the year. The nutraceutical business also lowered its adjusted EBITDA loss to S$1.43 million from S$1.90 million in FY2020. The decrease was mainly due to higher revenue earned during the year.

Review of financial position

Current assets of the Group increased to S$9.35 million from S$8.14 million, principally in our cash and cash equivalents and receivables. The increase in cash and cash equivalent was mainly due to net proceeds of S$10.18 million received from a private placement offset by cash outflow from operating activities and the purchase of manufacturing equipment. Receivables increased mainly due to additional accrual of R&D rebates for the Group and advances to subsidiaries for the Company.

Current liabilities of the Group increased to S$3.67 million from S$3.30 million. The increase was mainly due to reclassification of bank borrowings due within the next twelve months from non-current borrowings and recognition of lease liability arising from lease extensions.

During the year, the Company exercised its options to extend the leases of its office and staff accommodation for another two years and adjusted the right of use assets and lease liabilities accordingly for the Group and the Company.

During the year, we repaid some S$0.23 million in borrowings but, due to the appreciation of the Australian dollar, our total borrowings only decreased marginally to S$3.62 million from S$3.65 million.

Review of cash flow

Given the improved revenue and lower cash operating expenses, the Group recorded a lower cash used in operating activities before changes in working capital and taxes of S$8.76 million during FY2021 (FY2020: S$9.41 million). After payments for additional inventories and submission fee for the registration of Wafesil in Europe which was accrued in the previous year, net cash used in operating activities in FY2021 of S$8.35 million was comparable to that in FY2020 (FY2020: S$8.32 million).

The Group paid S$0.55 million in FY2021, principally for installation of freeze-drying related equipment.

The Group received net proceeds of S$10.18 million from the private placement of 44.49 million shares in September 2020. This was offset by repayments of borrowings, lease liabilities and interest totalling S$0.78 million. During FY2021, a pledged fixed deposit of $0.62 million was released by our bank.

2. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

Not applicable. No forecast or prospect statement had been previously disclosed to shareholders for the current reporting period.

3. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

COVID-19

The prolonged pandemic has led to an increasingly uncertain and challenging business environment.

In Australia, any movement restriction orders imposed by the Federal and State governments is likely to have a direct impact on retail foot traffic in the pharmacies and affect our sales in pharmacies. Such restrictions will also limit face-to-face sales calls and training meetings to be conducted with pharmacists and doctors as businesses seek to limit physical interactions in their stores and clinics. Whilst we have tried to minimise the impact and have initiated on-line meetings and training for doctors and pharmacists, the Group's ability to expand the sales of its nutraceutical products and medicinal cannabis products through pharmacies and clinics may be hindered to a considerable extent.

In addition to Australia, other markets of interest to our Group such as the US, EU and the UK have been severely impacted by the pandemic. Due to increasing uncertainties in the business environment, some companies may temporarily postpone committing to any substantial transactions.

Supply chain disruptions have led to increased costs and created intermittent logistical difficulties for the Group. Certain raw material costs have increased due to COVID-19 impacting our upstream suppliers. Uncertainties in transportation and freight schedules may result in longer lead-time in our procurement and delivery processes.

As health agencies globally prioritise their resources on COVID-19 related matters, this may lead to lengthening of review and approval timelines of the Group's products that have been or will be submitted for review.

Wafermine

In November 2020, we received endorsement from the European Medicines Agency (EMA) in its Scientific Advice to the Company regarding its Phase 3 clinical development programme for pain. With the successful outcome of the EMA Scientific Advice and End-of-Phase 2 meeting with the US FDA, the Company has now reached consensus with the regulators of the major markets of Europe and the United States on the remaining

clinical development required to support the approval of Wafermine in those markets. This consensus provides clarity to the costs and timeline of the Phase 3 programme and positions the Company well to continue out-licensing discussions with potential licensees.

In May 2021, the US FDA granted the Company an orphan drug designation for treatment of patients with CRPS with ketamine. Orphan drug designation provides certain benefits to the Company, including market exclusivity of seven years upon regulatory approval, tax credits for qualified clinical trials and waiver of the FDA's NDA filing fee of approximately US$2.9 million. The inclusion of CRPS adds to an already valuable Wafermine asset, which is currently being developed for acute moderate to severe pain and, potentially, major depressive disorder. CRPS opens up a new market with significant unmet medical need. This increases the attractiveness of Wafermine to licensees, who will be able to unlock substantially more value across multiple conditions.

Out-licensing Wafermine is a strategy that will allow us to fully unlock the value of the drug. A suitable partner will enable the Company to tap into its resources to fund, and expertise to run and complete, Phase 3 clinical development and obtain marketing approval for Wafermine. The Group can then access markets through its partners' infrastructure and sales networks to manage the commercialisation of the product more effectively. Although discussions on out-licensing of Wafermine are progressing, due to border closures and restrictions on face-to-face-meetings, we expect that certain parts of the process requiring physical presence and verifications will take longer to complete.

Medicinal Cannabis

In April 2020, we launched Xativa 12.5mg, a sublingual medicinal cannabis wafer containing CBD (cannabidiol) in Australia. Xativa 25mg was subsequently launched in 1H21. Xativa is available as an unregistered medicine by doctors' prescription under Special Access Scheme (SAS) and Authorised Prescriber pathway in Australia. We distribute Xativa via cannabis distributors such as Cannatrek Ltd or directly to pharmacies.

According to analysts, the legal medicinal cannabis market in Australia and New Zealand will be valued at US$1.55 billion in 2024[1]. Up to 30 June 2021, the TGA has approved over 130,000 SAS Category B applications for unapproved medicinal cannabis products. According to the TGA, applications were approved to use medicinal cannabis for a range of indications including pain, anxiety, insomnia, epilepsy, palliative care and spasticity from neurological conditions.

In December 2020, the occurrence of two major developments recognised the therapeutic potential for cannabis:

Firstly, the Australian TGA announced its final decision to down-schedule low dose CBD preparations from Schedule 4 (Prescription Medicine) to Schedule 3 (Pharmacist Only Medicine). The decision will allow TGA approved low-dose CBD products, up to a maximum of 150 mg/day, for use in adults, to be supplied over-the-counter by a pharmacist, without a prescription. We expect that this decision will result in registered CBD products being more widely accessible in pharmacies which may result in a greatly expanded market size. In view of the above, the Group has commenced preparations to support the registration of Xativa with TGA.

Secondly, the United Nations Commission on Narcotic Drugs (UN CND), the UN's central drug policy-making body, voted to remove cannabis from Schedule IV of the 1961 Single Convention on Narcotic Drugs (where it was listed for 59 years alongside deadly, addictive opioids including heroin) where the strictest control measures apply, to generally discourage its use for medical purposes. This action has the potential to stimulate global research into the therapeutic potential and public health effects of cannabis. Following UN CND's decision, the European Commission ruled that CBD would not be classified as a narcotic drug and confirmed that CBD consumables will be evaluated as food products under the Novel Foods regime.

In June 2021, the Company announced that Xativa had been granted export listing status by the TGA. Xativa's inclusion in the Australian Register of Therapeutic Goods list of drugs demonstrates that the product is compliant with strict standards that apply to products supplied domestically in Australia.

Following the grant of export listing status and the Group's successful expansion of wafer production capacity, the Company has entered into agreements with distribution partners for our medicinal cannabis products in Brazil and New Zealand. We intend to enter markets which have legalised the distribution and use of medicinal cannabis. This includes the US, Canada, and Europe, and build the Group as a global medicinal cannabis provider.

[1] Prohibition Partners, 2020, "The Oceania Cannabis Report, Second Edition, April 2020"

The Group plans to introduce other medicinal cannabis products containing THC (tetrahydrocannabinol) and CBD in various combinations and dosages to broaden the range to serve more patients. This will allow us to target and penetrate deeper, the entire addressable medicinal cannabis market.

Entity Health

Since the 2018 launch of Entity, the Group's nutraceuticals line, in Australia, we focused on penetrating the Australian market to establish Entity as a homegrown Australian health supplements brand. Australian-made health supplements are regarded by Chinese consumers as the gold standard of healthcare products due to Australia's reputation for safety and quality. Today, Entity products are sold in more than 250 pharmacies and health food stores in all major Australian cities.

In April 2020, we launched Entity flagship stores on JD Worldwide and Tmall Global. JD and Tmall are the two largest e-commerce platforms in China, commanding over 85% of the total B2C e-commerce market in China. Through these platforms, we are able to sell our nutraceutical products to the China consumers from Australia without lengthy and costly registration procedures to sell within the country. Chinese consumers have demonstrated an appetite for novel and sophisticated products which characterise the Entity line of nutraceuticals.

In the next 12 months we will continue to prioritise growing the market share for Entity products in China through cross-border e-commerce. We intend to introduce new products in categories popular or growing with China consumers, focusing on leveraging our unique, patented WaferiX sublingual technology to produce well-differentiated and scientifically advanced products that resonate with Chinese consumers.

Leverage WaferiX as a platform to develop new products

The WaferiX technology is a broadly applicable and highly versatile drug delivery platform. The technology consists of a rapidly disintegrating, fast-dissolving sublingual wafer designed to increase bioavailability and absorption of actives through the blood vessels under the tongue, to provide patient benefits of faster onset of therapeutic action and predictable and consistent dosing.

WaferiX has the ability to create market differentiation in response to expiring patents, generic encroachment, and declining new drug pipeline. We have identified certain conditions and actives that have the potential to benefit from WaferiX and now have broadened our product pipeline to include new therapeutic areas including psychiatry, oncology and vaccines.

In addition to developing our own pipeline of WaferiX products, there are significant opportunities to partner with other pharmaceutical companies.

Proposed Spin-off of Pharmaceuticals

On 12 June 2021, the Company announced that it is exploring the possibility of a spin-off of its pharmaceutical business (including medicinal cannabis) by way of a listing on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKEX") through Chapter 18A of the Rules Governing the Listing of Securities on the Stock Exchange (the "Proposed Spin-Off and Listing").

The Company intends to restructure its pharmaceutical business (including medicinal cannabis) to be held by Ligo Pharma Limited, a wholly-owned subsidiary which was incorporated on 31 March 2021 in the Cayman Islands (the "Spin-Off Company"). The restructuring and the Proposed Spin-Off and Listing are dependent on the results of preparatory work to be undertaken, requisite approvals from the relevant regulatory authorities, the then-prevailing market condition, investors' interests and response at the material time and any other relevant factors.

Following the restructuring, the Spin-Off Company will be engaged in manufacturing, research and development and sales of pharmaceutical and medicinal cannabis products (the "Pharmaceutical and Medicinal Cannabis Business"). These activities are currently undertaken by the Group's wholly-owned subsidiaries being iX Syrinx Pty Ltd, Arrow Property Trust, iX Biopharma Pty Ltd, iX Biopharma Europe Ltd and iXB Sdn Bhd.

Following the completion of the Proposed Spin-Off and Listing, the Company will focus on sales, marketing and distribution of innovative nutraceutical products under its brand Entity (the "Nutraceutical Business").

4. Whether the figures have been audited or reviewed, and in accordance with which auditing standard or practice.

The figures have not been audited nor reviewed by the Company's auditor.

5. Where the figures have been audited or reviewed, the auditors' report (including any qualifications modifications or emphasis of a matter).

Not applicable.

6. Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:

a. Updates on the efforts taken to resolve each outstanding audit issue.
b. Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.

This is not required for any audit issue that is a material uncertainty relating to going concern.

Not applicable.

7. If a decision regarding dividend has been made:

(a) Whether an interim (final) ordinary dividend has been declared (recommended); and

No dividend has been declared or recommended for the current reporting period.

(b) (i) Amount per share (cents)

Not applicable.

(b) (ii) Previous corresponding period (cents)

Not applicable.

(c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated).

Not applicable.

(d) The date the dividend is payable

Not applicable.

(e) Books closure date

Not applicable.

8. If no dividend has been declared (recommended), a statement to that effect.

No dividend has been declared or recommended for the current reporting period as the Company is in a loss position.

9. If the group has obtained a general mandate from shareholders for IPTs, the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

The Group does not have a general mandate for interested person transactions.

There was no interested person transaction of S$100,000 or more for FY2021.

10. Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1) of the listing manual.

The Company has procured undertakings from all its Directors and executive officers under Rule 720(1).

11. Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(10) in the format below. If there are no such persons, the issuer must make an appropriate negative statement.

Pursuant to Rule 704(10) of the Catalist Rules, there is no person occupying a managerial position in the Company or any of its principal subsidiaries who is related to a director or chief executive officer or substantial shareholder of the Company as at 30 June 2021.

12. A breakdown of the total annual dividend (in dollar value) for the issuer's latest full year and its previous full year.

Not applicable. No dividends have been declared or recommended for the financial years ended 30 June 2021 and 30 June 2020.

13. Use of Proceeds

a) 2020 Private Placement

Pursuant to the private placement of 44,491,299 ordinary shares, the Company received net proceeds of S$10.18 million ("Placement Proceeds"). As at 30 June 2021, the Placement Proceeds has been utilised as follows:

	Amount allocated	Amount utilised	Balance
	S$'000	**S$'000**	**S$'000**
To fund the development, manufacturing and marketing activities required for our pharmaceutical and nutraceutical products in the pipeline	6,108	(4,713)	1,395
General working capital purposes	4,072	(2,698)	1,374
Total	**10,180**	**(7,411)**	**2,769**

Details of working capital used:	**S$'000**
Professional fees	484
Payroll and directors' fees	916
Trademark and patents	69
Purchase of materials	386
Rental, office expenditure and other operating expenses	843
Total	**2,698**

The above utilisation of the Placement Proceeds is in accordance with the intended use as stated in the Company's announcement dated 28 July 2020.

b) Right Issue

Pursuant to the right issue of 48,814,711 shares on 26 July 2021, the Company received net proceeds of S$9.61 million which are allocated as follows in accordance with the intended use as stated in the Company's announcement dated 8 June 2021:

	Amount allocated
	S$'000
To fund manufacturing and marketing activities for the Group's products	7,610
General working capital purposes	2,000
Total	**9,610**

On behalf of the Board of Directors

Eddy Lee Yip Hang
Chairman & CEO

Albert Ho Shing Tung
Non-executive Director

23 August 2021

This announcement has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, UOB Kay Hian Private Limited (the "Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement including the accuracy, completeness and correctness of any of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President at 8 Anthony Road, #01-01, Singapore 229957, telephone: (65) 6590 6881.